342 related articles for article (PubMed ID: 28402949)
1. Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: "systems molecular imaging" of glucose metabolism.
Shen B; Huang T; Sun Y; Jin Z; Li XF
Oncotarget; 2017 Jun; 8(26):43536-43542. PubMed ID: 28402949
[TBL] [Abstract][Full Text] [Related]
2. The reverse Warburg effect and 18F-FDG uptake in non-small cell lung cancer A549 in mice: a pilot study.
Zhang G; Li J; Wang X; Ma Y; Yin X; Wang F; Zheng H; Duan X; Postel GC; Li XF
J Nucl Med; 2015 Apr; 56(4):607-12. PubMed ID: 25722447
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
Rajendran JG; Mankoff DA; O'Sullivan F; Peterson LM; Schwartz DL; Conrad EU; Spence AM; Muzi M; Farwell DG; Krohn KA
Clin Cancer Res; 2004 Apr; 10(7):2245-52. PubMed ID: 15073099
[TBL] [Abstract][Full Text] [Related]
4. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
5. Imaging of Tumor Metabolism Using Positron Emission Tomography (PET).
Apostolova I; Wedel F; Brenner W
Recent Results Cancer Res; 2016; 207():177-205. PubMed ID: 27557539
[TBL] [Abstract][Full Text] [Related]
6. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography: clinical applications in oncology. Part 1.
Kumar R; Nadig MR; Chauhan A
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1079-94. PubMed ID: 16336099
[TBL] [Abstract][Full Text] [Related]
8. [The value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) in diagnosis of neoplastic diseases].
Ruiz Hernández G; Romero de Avila Y Avalos C; Carreras Delgado JL
Med Clin (Barc); 2005 Feb; 124(6):229-36. PubMed ID: 15737307
[TBL] [Abstract][Full Text] [Related]
9. Imaging of tumor glucose utilization with positron emission tomography.
Buerkle A; Weber WA
Cancer Metastasis Rev; 2008 Dec; 27(4):545-54. PubMed ID: 18523732
[TBL] [Abstract][Full Text] [Related]
10. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage.
Busk M; Horsman MR; Jakobsen S; Bussink J; van der Kogel A; Overgaard J
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2294-303. PubMed ID: 18682937
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography.
Wijsman R; Kaanders JH; Oyen WJ; Bussink J
Q J Nucl Med Mol Imaging; 2013 Sep; 57(3):244-56. PubMed ID: 24045621
[TBL] [Abstract][Full Text] [Related]
12. Likely Common Role of Hypoxia in Driving
Yao Y; Li YM; He ZX; Civelek AC; Li XF
Cancer Biother Radiopharm; 2021 Oct; 36(8):624-631. PubMed ID: 34375126
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.
Li L; Hu M; Zhu H; Zhao W; Yang G; Yu J
Clin Lung Cancer; 2010 Sep; 11(5):335-40. PubMed ID: 20837459
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer.
Huang T; Civelek AC; Li J; Jiang H; Ng CK; Postel GC; Shen B; Li XF
J Nucl Med; 2012 Aug; 53(8):1262-8. PubMed ID: 22717978
[TBL] [Abstract][Full Text] [Related]
15. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
Kumar R; Hawkins RA; Yeh BM; Wang ZJ
Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
[TBL] [Abstract][Full Text] [Related]
16. Hyperglycemia and 18F-FDG PET/CT, issues and problem solving: a literature review.
Finessi M; Bisi G; Deandreis D
Acta Diabetol; 2020 Mar; 57(3):253-262. PubMed ID: 31304560
[TBL] [Abstract][Full Text] [Related]
17. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
Endo K; Oriuchi N; Higuchi T; Iida Y; Hanaoka H; Miyakubo M; Ishikita T; Koyama K
Int J Clin Oncol; 2006 Aug; 11(4):286-96. PubMed ID: 16937302
[TBL] [Abstract][Full Text] [Related]
18. The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation.
Riester M; Xu Q; Moreira A; Zheng J; Michor F; Downey RJ
Ann Oncol; 2018 Jan; 29(1):264-270. PubMed ID: 29045536
[TBL] [Abstract][Full Text] [Related]
19. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
[TBL] [Abstract][Full Text] [Related]
20. Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia.
Busk M; Horsman MR; Kristjansen PE; van der Kogel AJ; Bussink J; Overgaard J
Int J Cancer; 2008 Jun; 122(12):2726-34. PubMed ID: 18351643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
